Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma
Clinical trial NCT01302496 · COMPLETED
Trial details
- NCT number
- NCT01302496
- Sponsor
- Bart Neyns
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2011-02-01
- Primary completion
- 2013-10-01
- Enrollment
- 39
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.